2015 Global Survey on Liquid Biopsy Adoption Trends

Learn the Promising Technologies and Bottlenecks for CTCs and ctDNA—A Voice of Customer Study

USD 6,950

* Required Fields

USD 6,950

PAY BY INVOICE

Be the first to review this product

The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following:
•     Current and future use of liquid biopsy by organization type
•     Timeframe of liquid biopsy adoption amidst future users
•     Predominantly used cell types—CTCs, ctDNA, cfDNA and Evs—by organization type
•     Sample inflow to conduct liquid biopsy tests
•     Preference for sample types: blood, saliva, stool, serum, and so on.
•     Correlation analysis of sample type and biomarker type
•     Promising applications for liquid biopsy—current and future
•     Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
•     Technologies used to detect CtDNA—current vs. future users
•     Technologies used to detect CTCs
•     Vendor popularity for specific biomarkers and reimbursement scenario
•     Bottlenecks to mainstream implementation of liquid biopsy

Table of Contents

2015 Global Survey on Liquid Biopsy Adoption TrendsResearch Background, Objectives, Methodology, and Respondent DemographicsResearch ObjectivesResearch MethodologyResearch Methodology (continued)Respondent DemographicsRespondent Demographics (continued)Respondent Demographics—Current and Future UsersExecutive SummaryKey FindingsTop 7 Brands for Liquid BiopsyOverall Usage of Liquid BiopsyOverall Use of Liquid Biopsy by Organization TypeTimeframe for Future AdoptionTimeframe for Adoption by Organization TypeOpinion on Use of Liquid Biopsy as an Adjunct to Tissue BiopsyLiquid Biopsy as an Adjunct to Tissue Biopsy (continued)Preferred Cell Types and Sample Types for Liquid BiopsyOverall Biomarker UsageOverall Biomarker Usage—Hospital LaboratoriesOverall Biomarker Usage—Pharmaceutical and Diagnostic CompaniesOverall Biomarker Usage—Reference Laboratories*Overall Biomarker Usage—Research Institutes and UniversitiesWorkload AssessmentSample Volume Per MonthSample Format—OverallSample Format—Current Users vs. Future UsersSample Format by Organization TypePredominantly Used TechnologiesTechnologies Used to Detect ctDNA—Overview Technologies Used to Detect ctDNA—Current and Future User TrendsTechnologies Used to Detect ctDNA by Organization TypeTechnologies Used to Detect CTC—Overview Technologies Used to Detect CTC—Current and Future User TrendsTechnologies Used to Detect CTC by Organization TypeLiquid Biopsy—Promising Applications and BottlenecksBrand Familiarity for Tumor ProfilingPromising Applications of Liquid Biopsy (Overall)Promising Applications by Organization TypePromising Applications—Current and Future UsersBottlenecks in Liquid BiopsyBottlenecks by Biomarker TypeTumor Profiling Approaches, Technologies for DetectionLiquid Biopsy Usage to Profile TypesTumor Profiling by Organization Type Liquid Biopsy Approaches—Current vs. Future UsersLiquid Biopsy Approach by Organization TypeCorrelation of Sample Type and Liquid Biopsy ApproachCTC-Specific Liquid Biopsy Approaches—Current vs. Future UsersctDNA-Specific Liquid Biopsy Approaches—Current vs. Future UsersGermline or cfDNA-Specific Liquid Biopsy Approaches—Current vs. Future UsersEVs-Specific Liquid Biopsy Approaches—Current vs. Future Users Brand PerceptionOverall Brand PerceptionBrand Perception Organization TypeTop 7 Current and Future Brand PerceptionBrand Preference by Biomarker Type—CTCsBrand Preference by Biomarker Type—CtDNABrand Preference by Biomarker Type—Germline and cfDNABrand Preference by Biomarker Type—EvsReimbursement ScenarioReimbursement Trends (Overall)Reimbursement Trend by Organization TypeReimbursement by Technology—ctDNAReimbursement by Technology—CTCMutant Allele Limit (Verbatim Reponses)Mutant Allele Detection Limit—Diagnosis and MonitoringReasons for Preferring Blood as a Sample Type(Verbatim Reponses)Reasons for Choosing Blood Over Other Sample TypesReasons for Choosing Blood Over Other Sample Types (continued)Reasons for Choosing Blood Over Other Sample Types (continued)Reasons for Choosing Blood Over Other Sample Types (continued)Reasons for Choosing Blood Over Other Sample Types (continued)Legal DisclaimerAppendixAdditional Sources of InformationThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerNorth America and Europe PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 22-Nov-17

Region : North America

Release Date : 21-Nov-17

Region : North America

Release Date : 20-Nov-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.